🔬 They developed a unique process using CHO DG44 cells. This method resulted in high yields of the antibody.
📈 The biosimilar showed similar effectiveness to the original drug.
🧪 Further testing is needed before it can enter clinical trials.
Introduction:
The article discusses the development of a bioprocess for manufacturing a biosimilar version of atezolizumab, a monoclonal antibody used as a checkpoint inhibitor in cancer therapy. The research aims to establish a feasible production method as this therapeutic agent is set to go off patent, potentially increasing accessibility and affordability for patients.
- Mehmet Inan and colleagues designed a bioprocess using CHO DG44 cells to produce atezolizumab, which currently lacks a documented production method for a biosimilar in mammalian cells.
- Different transfection methods were tested to introduce viral genes into CHO DG44 cells, identifying a cell line that yielded the highest amounts of the antibody.
- The team optimized cell culture conditions in a batch-fed bioreactor, achieving antibody yields up to 800 mg/L using commercially available media and appropriate supplements.
- Purification of the produced biosimilar involved three forms of chromatography, which allowed comparison with the original commercial atezolizumab; results indicated similar functionality in binding to PD-L1.
- Further testing and studies, particularly toxicology assessments, are required before advancing the biosimilar to clinical trial phases, highlighting the lengthy path from drug development to patient application.
Conclusion:
The establishment of a bioprocess for producing a biosimilar of atezolizumab marks a significant advancement in biopharmaceutical development. As patents expire, such innovations could lead to more accessible cancer treatments, although the journey from laboratory production to therapeutic utilization remains complex and necessitates extensive validation.
